Log in to search using one of your social media accounts:

 

Statement Regarding Xifaxan Intellectual Property Litigation
LAVAL, Quebec, May 17, 2017 -- (Healthcare Sales & Marketing Network) -- Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Actavis Laboratories, Inc., at Actavis' request,... Biopharmaceuticals, Litigation Valeant Pharmaceuticals, Actavis Laboratories, Xifaxan, rifaximin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 17, 2017 Category: Pharmaceuticals Source Type: news

XIFAXAN (Rifaximin) Tablet [Avera McKennan Hospital]
Updated Date: Apr 14, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - April 14, 2017 Category: Drugs & Pharmacology Source Type: news

XIFAXAN (Rifaximin) Tablet [Cardinal Health]
Updated Date: Mar 15, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - March 15, 2017 Category: Drugs & Pharmacology Source Type: news

XIFAXAN (Rifaximin) Tablet [A-S Medication Solutions]
Updated Date: Feb 10, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - February 10, 2017 Category: Drugs & Pharmacology Source Type: news

Economics of Treating Hepatic Encephalopathy With Rifaximin-a Economics of Treating Hepatic Encephalopathy With Rifaximin-a
Rifaximin-alpha is effect in treating hepatic encephalopathy, but its cost is high. Might it still be cost-saving due to reduced hospital admissions and shorter stays?Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 22, 2016 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
DUBLIN, Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today announced that the Company has received an Acceptable for Filing letter from the U.S. Food and Drug Administration (FDA) ... Biopharmaceuticals, Generics, Gastroenterology, FDAAllergan, Valeant Pharmaceuticals, IFAXAN, rifaximin, irritable bowel syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 29, 2016 Category: Pharmaceuticals Source Type: news

Electronic program reduces cirrhosis readmission rates
An electronic quality improvement initiative for patients with cirrhosis has achieved significant reductions in 30-day readmission rates. The program’s goals included universal use of rifaximin and... (Source: Family Practice News)
Source: Family Practice News - February 25, 2016 Category: Primary Care Source Type: news

Liver Cirrhosis Treatment May Curb Cerebral EdemaLiver Cirrhosis Treatment May Curb Cerebral Edema
Lactulose and rifaximin treatment of cirrhosis patients with minimal hepatic encephalopathy (MHE) reverses low-grade cerebral edema, according to researchers from India. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 29, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Monthly News Roundup - May 2015
Viberzi and Xifaxan FDA-Approved For Diarrhea-Predominant IBS Irritable bowel syndrome with diarrhea (IBS-D) may affect up to 15 million Americans, especially women, and treatment options are limited. In response, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 31, 2015 Category: Pharmaceuticals Source Type: news

Rifaximin for IBS: Where Do We Stand?Rifaximin for IBS: Where Do We Stand?
Dr David Johnson reviews the latest data on rifaximin treatment for diarrhea-predominant irritable bowel syndrome. Medscape Gastroenterology (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 29, 2015 Category: Drugs & Pharmacology Tags: Gastroenterology Commentary Source Type: news

FDA Approves Two New Treatments for Diarrhea-Predominant IBS (FREE)
By Kristin J. Kelley Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS Eluxadoline (Viberzi) and rifaximin (Xifaxan) have both been approved to treat irritable bowel syndrome with diarrhea. The approvals … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 29, 2015 Category: Primary Care Source Type: news

After Salix acquisition, Valeant receives FDA approval for IBS-D drug
Shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) traded up about 1.5 percent after markets closed Wednesday on news that the U.S. Food and Drug Administration approved the drug Xifaxan to treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. Quebec's Valeant acquired Xifaxan when it bought Raleigh’s Salix Pharmaceuticals for $11 billion, or $173 per share in cash, in April. Already, Xifaxan was Salix’s biggest seller, but the new indication could drive… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 28, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news

FDA OKs Eluxadoline and Rifaximin for IBS With DiarrheaFDA OKs Eluxadoline and Rifaximin for IBS With Diarrhea
The drugs from two separate companies relieve pain and improve stool consistency for patients with IBS along with diarrhea. FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 27, 2015 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news

After Salix acquisition, Valeant receives FDA approval for IBS-D drug
Shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) traded up about 1.5 percent after markets closed Wednesday on news that the U.S. Food and Drug Administration approved the drug Xifaxan to treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. Quebec's Valeant acquired Xifaxan when it bought Raleigh’s Salix Pharmaceuticals for $11 billion, or $173 per share in cash, in April. Already, Xifaxan was Salix’s biggest seller, but the new indication could drive… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - May 27, 2015 Category: Hospital Management Authors: Jason deBruyn Source Type: news

FDA approves two therapies to treat IBS-D
The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 27, 2015 Category: American Health Source Type: news

FDA Approves Two Therapies to Treat Irritable Bowel Syndrome with Diarrhea (IBS-D)
May 27, 2015 -- The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2015 Category: Pharmaceuticals Source Type: news

Lupin launches anti-bacterial Zaxine tablets in Canada
Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with HE, a complication of liver disease (cirrhosis). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 20, 2015 Category: Pharmaceuticals Source Type: news

Treating the Root Cause of IBS: Small Intestine Bacterial Overgrowth
Rosie is a 30-year-old banker with very long work hours who came to see me with symptoms of gas, bloating and constipation. She had stomach cramps after eating, stubborn acne and a weight gain of 10 pounds in the last couple years despite a good diet and exercising regularly. A visit to a gastroenterologist had yielded the diagnosis of irritable bowel syndrome (IBS) after testing that included an endoscopy, a colonoscopy, blood work, and an MRI -- all of which were essentially normal. Rosie's doctor prescribed Amitiza, a drug typically given for constipation, which caused her nausea and abdominal pain. She stopped taking i...
Source: Healthy Living - The Huffington Post - April 1, 2015 Category: Consumer Health News Source Type: news

Bidding war for Salix shows confidence in its lead drug
The bidding war for Raleigh's Salix Pharmaceuticals (Nasdaq: SLXP) shows that Valeant (NYSE: VRX) has high confidence that Salix will receive a secondary approval for its biggest selling drug Xifaxan. Specifically, Salix applied with the U.S. Food and Drug Administration to sell Xifaxan as a treatment for irritable bowel syndrome with diarrhea, or IBS-D, something analysts predict will significantly increase revenue. Indeed, it is this indication for this drug that has made Salix become such an… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 16, 2015 Category: Pharmaceuticals Authors: Jason deBruyn Source Type: news

Rifaximin gets the OK from NICE for hepatic encephalopathy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news

TARGET 3: Rifaximin Safe to Reuse for Irritable BowelTARGET 3: Rifaximin Safe to Reuse for Irritable Bowel
Retreatment with rifaximin is safe and effective, report TARGET investigators. And long-term use of linaclotide is well tolerated. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 27, 2014 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

IBS Yields to Rifaximin -- Repeatedly
(MedPage Today) -- Antibiotic works in first-time and relapsed diarrhea-predominant irritable bowel syndrome. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 22, 2014 Category: Gastroenterology Source Type: news

Cipla Ltd grants Salix Pharmaceuticals Ltd rights for Rifaximin
Under the agreement, Salix will make an upfront payment and milestone payments to Cipla, the companies said in separate statements. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 18, 2014 Category: Pharmaceuticals Source Type: news

XIFAXAN (Rifaximin) Tablet [Carilion Materials Management]
Updated Date: Aug 20, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 20, 2014 Category: Drugs & Pharmacology Source Type: news

The Effects of Rifaximin in Hepatic EncephalopathyThe Effects of Rifaximin in Hepatic Encephalopathy
How well does rifaximin work in the management of hepatic encephalopathy, in terms of prevention as well as the treatment of acute episodes? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2014 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Treating Overt Hepatic EncephalopathyTreating Overt Hepatic Encephalopathy
Is rifaximin more successful in treating hepatic encephalopathy on its own or in combination with lactulose? The American Journal of Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Rifaximin Reduces Risk of Traveler's DiarrheaRifaximin Reduces Risk of Traveler's Diarrhea
Prophylaxis with oral rifaximin halved the risk of diarrhea during travel to south and southeast Asia in a phase III trial. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 7, 2013 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Rifaximin Improves Treatment of Hepatic EncephalopathyRifaximin Improves Treatment of Hepatic Encephalopathy
Adding rifaximin to lactulose improves the treatment of overt hepatic encephalopathy, researchers from India report. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Xifaxan Discount Card Now Available at MedicationDiscountCard.com
Fight Effects of E. Coli with Xifaxan Discount Cards(PRWeb June 06, 2013)Read the full story at http://www.prweb.com/releases/2013/xifaxan-coupon/prweb10800436.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 7, 2013 Category: Pharmaceuticals Source Type: news

PBAC Approves XIFAXAN(R) (Rifaxamin and#945;) 550 mg Cost Effectiveness in Australia
LONDON, May 24, 2013 -- (Healthcare Sales & Marketing Network) --Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrenc... Biopharmaceuticals, RegulatoryNorgine, Alfa Wassermann, XIFAXAN, TARGAXAN, hepatic encephalopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 24, 2013 Category: Pharmaceuticals Source Type: news

XIFAXAN (Rifaximin) Tablet [Salix Pharmaceuticals, Inc.]
Updated Date: May 14, 2013 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - May 14, 2013 Category: Drugs & Pharmacology Source Type: news

Targaxan® (rifaximin) launched in the UK for hepatic encephalopathy
Source: EMC Area: News Targaxan® (rifaximin) tablets have been launched in the UK for reducing recurrence of episodes of overt hepatic encephalopathy in adult patients. Rifaximin is already licensed in the UK as the brand name Xifaxanta® for the treatment of travellers' diarrhoea.   The NHS list price is £259.23 for 56 tablets (Source: NeLM - News)
Source: NeLM - News - February 22, 2013 Category: Drugs & Pharmacology Source Type: news

Drugs Market: Comprehensive Patent Search Analysis for Vemurafenib,...
Comprehensive patent search for Vemurafenib, Colesevelam, Rifaximin, Nevirapine, Liraglutide, Vilazodone, Hexylaminolevulinic Acid and Treprostinil in new market research reports at...(PRWeb February 19, 2013)Read the full story at http://www.prweb.com/releases/drugs-comprehensive/patent-search-analysis/prweb10444767.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 19, 2013 Category: Pharmaceuticals Source Type: news

Rifaximin in the Treatment of Recurrent C. DifficileRifaximin in the Treatment of Recurrent C. Difficile
Is rifaxmin a viable antibiotic choice for the treatment of recurrent C. difficile infection? How does it compare to other antibiotics? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

DTB: Rifaximin for the treatment of travellers' diarrhoea
Source: Drug and Therapeutics Bulletin (DTB) Area: Evidence> Drug Specific Reviews This review in the Drug and Therapeutics Bulletin (DTB) discusses the evidence for rifaximin and how it fits in with current management strategies for travellers' diarrhoea.   The review concludes that the evidence does not suggest benefit for rifaximin over existing standard treatments in the management of travellers' diarrhoea. (Source: NeLM - Drug Specific Reviews)
Source: NeLM - Drug Specific Reviews - January 9, 2013 Category: Drugs & Pharmacology Source Type: news